(Q46698119)

24 December 2017

title

Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation (English)

1 reference

24 December 2017

main subject

1-methyltryptophan

1 reference

ChEBI release 2020-05-28

8

Kunle Odunsi

1 reference

24 December 2017

author name string

Feng Qian

1

1 reference

24 December 2017

Jianqun Liao

2

1 reference

24 December 2017

Jeannine Villella

3

1 reference

24 December 2017

Robert Edwards

4

1 reference

24 December 2017

Pawel Kalinski

5

1 reference

24 December 2017

Shashikant Lele

6

1 reference

24 December 2017

Protul Shrikant

7

1 reference

24 December 2017

publication date

22 April 2012

1 reference

24 December 2017

Cancer Immunology, Immunotherapy

published in

1 reference

24 December 2017

volume

61

1 reference

24 December 2017

issue

11

1 reference

24 December 2017

page(s)

2013-2020

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1007/s00262-012-1265-x

exact match

0 references

cites work

Creating immune privilege: active local suppression that benefits friends, but protects foes.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Tolerance, DCs and tryptophan: much ado about IDO

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

IDO expression by dendritic cells: tolerance and tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

1-L-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-D-methyltryptophan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1265-X

10.1007/S00262-012-1265-X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

22527253

1 reference

24 December 2017